![]() | |
Names | |
---|---|
Preferred IUPAC name
N,N-Dimethyl-4,4-diphenylheptan-2-amine | |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H29N | |
Molar mass | 295.4668 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Methade, or 6-(dimethylamino)-4,4-diphenylheptane, is the parent compound of the methadone and methadol series of opioid analgesics: [1]
Derived from the chemical structure of
methadone, various analogs and derivatives have been synthesized and developed to enhance its therapeutic properties and minimize potential side effects. Methadone itself is a synthetic
opioid that exhibits potent
analgesic properties, making it effective in relieving moderate to severe
pain. It acts on the
central nervous system, specifically targeting
opioid receptors in the
brain and spinal cord to alleviate pain signals.
One of the notable applications of methadone is in the treatment of opioid addiction. It has been widely used as a substitution therapy for individuals addicted to opioids, such as heroin or prescription painkillers. Methadone treatment helps to reduce withdrawal symptoms and cravings, allowing individuals to stabilize their lives and gradually taper off opioids under medical supervision.
The methadone series of opioids, which share a structural similarity to methadone, have been developed with the aim of improving therapeutic efficacy and safety profiles. These analogs and derivatives undergo rigorous testing and clinical trials to ensure their effectiveness, tolerability, and potential for abuse.
It is important to note that methadone and its derivatives are potent opioids with the potential for addiction and misuse. Therefore, their use is strictly regulated and monitored by healthcare professionals to ensure safe and appropriate administration.
The methade series includes the following compounds:
Some related compounds include:
![]() | |
Names | |
---|---|
Preferred IUPAC name
N,N-Dimethyl-4,4-diphenylheptan-2-amine | |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H29N | |
Molar mass | 295.4668 g/mol |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Methade, or 6-(dimethylamino)-4,4-diphenylheptane, is the parent compound of the methadone and methadol series of opioid analgesics: [1]
Derived from the chemical structure of
methadone, various analogs and derivatives have been synthesized and developed to enhance its therapeutic properties and minimize potential side effects. Methadone itself is a synthetic
opioid that exhibits potent
analgesic properties, making it effective in relieving moderate to severe
pain. It acts on the
central nervous system, specifically targeting
opioid receptors in the
brain and spinal cord to alleviate pain signals.
One of the notable applications of methadone is in the treatment of opioid addiction. It has been widely used as a substitution therapy for individuals addicted to opioids, such as heroin or prescription painkillers. Methadone treatment helps to reduce withdrawal symptoms and cravings, allowing individuals to stabilize their lives and gradually taper off opioids under medical supervision.
The methadone series of opioids, which share a structural similarity to methadone, have been developed with the aim of improving therapeutic efficacy and safety profiles. These analogs and derivatives undergo rigorous testing and clinical trials to ensure their effectiveness, tolerability, and potential for abuse.
It is important to note that methadone and its derivatives are potent opioids with the potential for addiction and misuse. Therefore, their use is strictly regulated and monitored by healthcare professionals to ensure safe and appropriate administration.
The methade series includes the following compounds:
Some related compounds include: